Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Transfus Apher Sci ; 60(4): 103155, 2021 Aug.
Article in English | MEDLINE | ID: mdl-33975808

ABSTRACT

Allogeneic peripheral blood-derived (PBS) serum eye drops have been largely used in the treatment of dry eye disease (DED). Recently, cord blood has emerged as an effective alternative serum source (cord blood serum, CBS), containing a higher amount of growth factors than PBS, it holds the promise of a better capability to stimulate corneal healing. However, the lack of a standardized method for preparation, dispensation, storage and a poor biochemical characterization still hamper the establishment of a clinical consensus. Here the metabolomes of the two different serum eye drop preparations were compared using proton nuclear magnetic resonance spectroscopy. We found that both PBS and CBS contained several organic compounds, the majority of them already detected in human tears and may be thereby considered lacrimal substitutes. Metabolites having in the multivariate statistical analysis Partial least squares discriminant analysis (PLS-DA) a VIP scores > 1.0 were considered to be significantly different. All the metabolites identified were found to have a p < 0.05 in the univariate analysis. CBS, in particular, showed the highest amount of choline, myo-inositol, glutamine, creatine and ß-hydroxybutyrate. These evidences constitute relevant advances towards serum eye drops characterization and confirm that cord blood is a valid alternative source of serum eye drops.


Subject(s)
Dry Eye Syndromes/drug therapy , Fetal Blood/chemistry , Ophthalmic Solutions/administration & dosage , Serum , Adult , Cornea/metabolism , Cornea/pathology , Dry Eye Syndromes/metabolism , Dry Eye Syndromes/pathology , Female , Humans , Male , Middle Aged , Ophthalmic Solutions/chemistry , Prospective Studies
2.
Molecules ; 22(6)2017 May 27.
Article in English | MEDLINE | ID: mdl-28555002

ABSTRACT

Resveratrol (RSV) is a well known chemopreventive molecule featuring anti-cancer properties. Our paper describes the main molecular targets of RSV linked to its antiproliferative activity on lymphoma and leukemia experimental models. It discusses further the most recent and most promising among these molecular targets for a translational application.


Subject(s)
Anticarcinogenic Agents/therapeutic use , Leukemia/drug therapy , Lymphoma/drug therapy , Stilbenes/therapeutic use , Humans , Resveratrol
SELECTION OF CITATIONS
SEARCH DETAIL
...